

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.

上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

**SUPPLEMENTAL ANNOUNCEMENT
DISCLOSEABLE TRANSACTION
FORMATION OF THE LIMITED PARTNERSHIP**

Reference is made to the announcements of the Company dated December 6, 2024 and December 23, 2024 in relation to the formation of the Limited Partnership (the “**Announcements**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as defined in the Announcements.

CHANGE IN CAPITAL CONTRIBUTION

Pursuant to the Limited Partnership Agreement, the total capital contribution of the Limited Partnership shall be RMB54.30 million, of which RMB0.01 million, RMB32.8 million and RMB21.49 million shall be contributed by Guojian Jinquan, the Company and Mr. Jing BAO, representing approximately 0.0184%, 60.4052% and 39.5764% of the total capital contribution, respectively.

On December 26, 2024, the Company, Guojian Jinquan and Mr. Jing Bao entered into a supplemental agreement to the Limited Partnership Agreement (the “**Supplemental Agreement**”), pursuant to which the parties have agreed to change the total capital

contribution of Limited Partnership from RMB54.30 million to RMB55.35 million, and the details of the capital contribution by each partner are set out below:

Partners	Total committed capital (RMB)	Approximate proportion of committed capital of each partner (%)
Guojian Jinquan	1,060,000	1.9151
the Company	32,800,000	59.2593
Mr. Jing Bao	21,490,000	38.8256
Total	55,350,000	100.0000

Save as disclosed above, all other terms and conditions of the Limited Partnership Agreement shall remain unchanged and continue to be in full force and effect.

By Order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive director

Shanghai, the People's Republic of China, December 26, 2024

As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive director, Mr. Yunqing WANG and Ms. Peili WANG as executive directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive directors.